<div id="readability-page-1"><p><span>DexCom (NASDAQ:DXCM - Get Free Report)</span> had its target price reduced by investment analysts at Bank of America  from $100.00 to $80.00 in a report issued on Monday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the medical device company's stock. Bank of America's price target points to a potential upside of 24.46% from the stock's current price.</p><ul><li>Sell in May and Go Away—Starting With These 3 Stocks</li></ul><p>Other equities research analysts have also issued reports about the stock. Citigroup  reissued a &#34;buy&#34; rating and issued a $79.00 target price (down from $84.00) on shares of DexCom in a report on Monday, May 4th. TD Cowen reduced their price objective on shares of DexCom from $84.00 to $75.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, May 1st. Mizuho  set a $75.00 price objective on shares of DexCom in a research report on Friday, May 1st. Raymond James Financial  set a $81.00 price objective on shares of DexCom in a research report on Friday, May 1st. Finally, Evercore upgraded shares of DexCom from an &#34;in-line&#34; rating to an &#34;outperform&#34; rating and set a $90.00 price objective on the stock in a research report on Tuesday, March 24th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned  a Buy rating, three have assigned  a Hold rating and one  has given a Sell rating to the company. According to data from MarketBeat, DexCom presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $82.21.</p><p><b>View Our Latest Report on DXCM</b></p><h2>DexCom Stock Performance</h2><ul><li>3 Reasons Analysts Love DexCom</li></ul><p>DexCom stock traded up $2.65 during midday trading on Monday, hitting $64.28. The stock had a trading volume of 5,059,238 shares, compared to its average volume of 5,045,384. The firm's fifty day moving average is $63.46 and its two-hundred day moving average is $65.85. The company has a market capitalization of $24.80 billion, a PE ratio of 27.43, a P/E/G ratio of 1.06 and a beta of 1.40. DexCom has a 52-week low of $54.11 and a 52-week high of $89.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. </p><p>DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm's quarterly revenue was up 15.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 EPS.  On average, research analysts forecast that  DexCom will post 2.56 EPS for the current year. </p><h2>Insider Buying and Selling</h2><ul><li>From Dividends to Growth: Why These 3 Stocks Stand Out in 2025</li></ul><p>In other news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the transaction, the executive vice president directly owned 111,204 shares in the company, valued at approximately $7,010,300.16. This represents a 1.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director owned 25,007 shares of the company's stock, valued at $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,412 shares of company stock valued at $278,143 over the last quarter. Corporate insiders own  0.28% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds and other institutional investors have recently modified their holdings of the company. Trust Co. of Vermont boosted its position in shares of  DexCom by 14.8% during the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company's stock valued at $74,000 after acquiring an additional 145 shares during the last quarter.  CVA Family Office LLC boosted its position in shares of  DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company's stock valued at $30,000 after acquiring an additional 147 shares during the last quarter.  V Square Quantitative Management LLC boosted its position in shares of  DexCom by 1.8% during the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company's stock valued at $604,000 after acquiring an additional 172 shares during the last quarter.  Essex Financial Services Inc. boosted its position in shares of  DexCom by 5.7% during the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company's stock valued at $204,000 after acquiring an additional 175 shares during the last quarter.  Finally, IFP Advisors Inc boosted its stake in  DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company's stock worth $61,000 after buying an additional 178 shares during the period. 97.75% of the stock is currently owned by institutional investors. </p><h2>DexCom Company Profile</h2> (Get Free Report)<p>DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.  </p><p>Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.</p><h2>Read More</h2><ul><li>Five stocks we like better than DexCom</li><li>Why Applied Optoelectronics Stock May Be Near a Turning Point</li><li>From High-Yield to High-Growth: 3 Stocks Boosting Dividends</li><li>Is Everspin Technologies the Next AI Edge Breakout?</li><li>5 Robotics Stocks to Watch as Physical AI Builds Momentum</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in DexCom Right Now?</h2><p>Before you consider DexCom, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.</p><p>While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

DXCM

<p>Bank of America has lowered its price target for DexCom (NASDAQ:DXCM) from $100.00 to $80.00 while maintaining a 'buy' rating. Other analysts have also adjusted their targets, with Citigroup setting a target of $79.00 and TD Cowen at $75.00. DexCom's stock is currently trading at $64.28, with a potential upside of 24.46% from the new target. The company reported earnings of $0.56 per share, exceeding estimates, and has a market cap of $24.80 billion.</p>

Market Beat

DexCom

SPDR S&P Biotech

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

iShares US Medical Devices

SPDR S&P Health Equip

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Bank of America

Citigroup

Mizuho Financial

Mizuho Financial Group, Inc.

Raymond James Financial

Evercore

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

CITIGROUP INC 6.250 NON CUM SER II PFD WI

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Bank of America Lowers DexCom (NASDAQ:DXCM) Price Target to $80.00